Evidence map›Paper›PMID 28420434›Full record

ArticleStem cell research & therapy2017

The neuroprotective effects of human bone marrow mesenchymal stem cells are dose-dependent in TNBS colitis.

Ainsley M Robinson, Ahmed A Rahman, Sarah Miller, Rhian Stavely, Samy Sakkal, Kulmira Nurgali

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell research & therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Enteric nervous system as a therapeutic target in gastrointestinal disorders.World journal of gastrointestinal pharmacology and therapeutics · 2025
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Ainsley M RobinsonCollege of Health and Biomedicine, Victoria University, Melbourne, VIC, Australia.
Ahmed A RahmanCollege of Health and Biomedicine, Victoria University, Melbourne, VIC, Australia.
Sarah MillerCollege of Health and Biomedicine, Victoria University, Melbourne, VIC, Australia.
Rhian StavelyCollege of Health and Biomedicine, Victoria University, Melbourne, VIC, Australia.
Samy SakkalCollege of Health and Biomedicine, Victoria University, Melbourne, VIC, Australia.
Kulmira NurgaliCollege of Health and Biomedicine, Victoria University, Melbourne, VIC, Australia. kulmira.nurgali@vu.edu.au.
Victoria University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe incidence of inflammatory bowel diseases (IBD) is increasing worldwide with patients experiencing severe impacts on their quality of life. It is well accepted that intestinal inflammation associates with extensive damage to the enteric nervous system (ENS), which intrinsically innervates the gastrointestinal tract and regulates all gut functions. Hence, treatments targeting the enteric neurons are plausible for alleviating IBD and associated complications. Mesenchymal stem cells (MSCs) are gaining wide recognition as a potential therapy for many diseases due to their immunomodulatory and neuroprotective qualities. However, there is a large discrepancy regarding appropriate cell doses used in both clinical trials and experimental models of disease. We have previously demonstrated that human bone marrow MSCs exhibit neuroprotective and anti-inflammatory effects in a guinea-pig model of 2,4,6-trinitrobenzene-sulfonate (TNBS)-induced colitis; but an investigation into whether this response is dose-dependent has not been conducted.

methodsHartley guinea-pigs were administered TNBS or sham treatment intra-rectally. Animals in the MSC treatment groups received either 1 × 10

resultsMSCs administered at a low dose, 1 × 10

conclusionsThe neuroprotective effect of MSCs in TNBS colitis is dose-dependent. Increasing doses higher than 1 × 10

Indexed as

AnimalsCell LineColitis, UlcerativeColonFemaleGuinea PigsHumansMaleMesenchymal Stem CellsMesenchymal Stem Cell TransplantationNeuronsTrinitrobenzenesulfonic AcidTrinitrobenzenesulfonic AcidDose-dependenceEnteric neuronsInflammatory bowel diseaseIntestinal inflammationMesenchymal stem cells

Identifiers

PMID28420434
PMCPMC5395912
OpenAlexW2605959280

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.